NCT03599193View on ClinicalTrials.gov

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

Tazarotene Lotion, 0.1%

DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off

DRUG

Tazarotene Cream, 0.1%

Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours

Trial Locations (2)

73301

Dr. DuBois, Austin

Dr. Jones, Austin

Sponsors
All Listed Sponsors
lead

Dr. Reddy's Laboratories Limited

INDUSTRY